Provided by Tiger Trade Technology Pte. Ltd.

Immunovant, Inc.

27.49
+0.44001.63%
Post-market: 27.36-0.1300-0.47%19:46 EST
Volume:1.95M
Turnover:53.26M
Market Cap:5.60B
PE:-10.26
High:27.92
Open:27.69
Low:26.25
Close:27.05
52wk High:27.92
52wk Low:12.72
Shares:203.53M
Float Shares:89.02M
Volume Ratio:1.03
T/O Rate:2.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.6799
EPS(LYR):-2.7303
ROE:-69.35%
ROA:-41.33%
PB:5.67
PE(LYR):-10.07

Loading ...

Immunovant Is Maintained at Buy by Guggenheim

Dow Jones
·
Yesterday

Immunovant (IMVT) Receives a Buy from J.P. Morgan

TIPRANKS
·
Yesterday

Immunovant price target raised to $44 from $41 at Guggenheim

TIPRANKS
·
Yesterday

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Immunovant (IMVT) and Roivant Sciences (ROIV)

TIPRANKS
·
Yesterday

Stock Track | Immunovant Soars 11.72% Intraday on Better-Than-Expected Q3 Results and Strong Financial Position

Stock Track
·
Feb 06

Stock Track | Immunovant Soars 7.40% in Pre-market on Better-Than-Expected Q3 Results and Strong Cash Position

Stock Track
·
Feb 06

Earnings Flash (IMVT) Immunovant Posts Fiscal Q3 Loss $0.61 a Share, vs. FactSet Est of $0.69 Loss

MT Newswires Live
·
Feb 06

Immunovant Q3 net loss smaller than expected

Reuters
·
Feb 06

Immunovant Q3 EPS $(0.61) Beats $(0.71) Estimate

Benzinga
·
Feb 06

BRIEF-Immunovant Q3 Net Income USD -110.635 Million Vs. IBES Estimate USD -125.1 Million

Reuters
·
Feb 06

Immunovant Q3 Basic EPS USD -0.61

THOMSON REUTERS
·
Feb 06

Immunovant Q3 Net Income USD -110.635 Million VS. Ibes Estimate USD -125.1 Million

THOMSON REUTERS
·
Feb 06

Immunovant Q3 Operating Expenses USD 114.362 Million

THOMSON REUTERS
·
Feb 06

Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

THOMSON REUTERS
·
Feb 06

Earning Preview: Immunovant, Inc. this quarter’s revenue is expected to increase by 0.00%, and institutional views are bullish

Earnings Agent
·
Jan 30

Immunovant Inc. to Announce Third Quarter Financial Results and Business Update

Reuters
·
Jan 26

Roivant Sciences President and Immunovant CEO Eric Venker Reports Disposal of Common Shares

Reuters
·
Jan 15

Immunovant price target raised to $22 from $16 at Truist

TIPRANKS
·
Jan 08

Immunovant Raised to Outperform From Peer Perform by Wolfe Research

Dow Jones
·
Jan 06

Roivant Sciences President and Immunovant CEO Eric Venker Reports Disposal of Common Shares

Reuters
·
Dec 30, 2025